Plain-English translation of NCT06629324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing autologous bone marrow-derived mononuclear cell transplantation—a treatment where doctors take cells from a child's own bone marrow and inject them into the spinal fluid to help improve movement and reduce muscle stiffness in children with cerebral palsy. The treatment is combined with physical rehabilitation. Researchers want to see if this approach can help children move better and improve their overall quality of life.
Cerebral palsy is one of the most common causes of movement problems in children, and current treatments don't always fully restore function. Recent studies suggest that this medication may help improve motor function and reduce muscle stiffness, but more research is needed to confirm how well it works and whether it can improve quality of life for children and their families.
You likely qualify if…
You likely don't qualify if…
If you are in the first group, you will receive two bone marrow cell transplants—one at the start of the study and another 6 months later—along with a rehabilitation program. If you are in the second group, you will first do rehabilitation alone for several months, then receive the cell transplants later in the study. Either way, you will have follow-up visits over about 18 months so doctors can measure changes in your child's movement, muscle tone, and overall quality of life.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Vietnam